Abstract:Rho-associated protein kinases (ROCK1 and ROCK2) are promising targets for a number of diseases, including cardiovascular disorders, nervous system diseases, cancers, etc. Recently, we have successfully identified a ROCK1 inhibitor (1) with the triazine core. In order to gain a deeper insight into the microscopic binding of this inhibitor with ROCK1 and design derivatives with improved potency, the interactions between ROCK1 and a series of triazine/pyrimidine-based inhibitors were studied by using an integrated computational protocol that combines molecular docking, molecular dynamics (MD) simulations, binding free energy calculations, and binding energy decomposition analysis. First, three docking protocols, rigid receptor docking, induced fit docking, QM-polarized ligand docking, were used to determine the binding modes of the studied inhibitors in the active site of ROCK1. The results illustrate that rigid receptor docking achieves the best performance to rank the binding affinities of the studied inhibitors. Then, based on the predicted structures from molecular docking, MD simulations and MM/GBSA free energy calculations were employed to determine the dynamic binding process and compare the binding modes of the inhibitors with different activities. The binding free energies predicted by MM/GBSA are in good agreement with the experimental bioactivities, and the analysis of the individual energy terms suggests that the van der Waals interaction is the major driving force for ligand binding. In addition, the residue-inhibitor interaction spectra were obtained by the MM/GBSA free energy decomposition analysis, and the important residues for achieving strong binding were highlighted, which affords important guidance for the rational design of novel ROCK inhibitors. Finally, a variety of derivatives of inhibitor 1 were designed and four of them showed promising potency according to the predictions. We expect that our study can provide significant insight into the development of improved inhibitors of ROCK1.

Discovery of 1,2,4-Triazole-3-thione Derivatives as Potent and Selective DCN1 Inhibitors for Pathological Cardiac Fibrosis and Remodeling

Discovery of Potent and Selective 2-(Benzylthio)pyrimidine-based DCN1-UBC12 Inhibitors for Anticardiac Fibrotic Effects

Development of phenyltriazole thiol-based derivatives as highly potent inhibitors of DCN1-UBC12 interaction

Design, Synthesis, And Interaction Study Of Quinazoline-2(1h)-Thione Derivatives As Novel Potential Bcl-X(L) Inhibitors

The Discovery of Novel ACA Derivatives As Specific TRPM2 Inhibitors That Reduce Ischemic Injury Both in Vitro and in Vivo.

Discovery of 2-Aminopyrimidine Derivatives As Potent Dual FLT3/CHK1 Inhibitors with Significantly Reduced Herg Inhibitory Activities.

Discovery of 1,3,4-oxadiazole derivatives containing a bisamide moiety as a novel class of potential cardioprotective agents

Design, synthesis and structure-activity relationship of 1,8-naphthalimide derivatives as highly potent hCYP1B1 inhibitors

Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.

Design, Synthesis, and Structure-Activity Relationships of 1,2,3-Triazole Benzenesulfonamides As New Selective Leucine-Zipper and Sterile-α Motif Kinase (ZAK) Inhibitors.

Design and Synthesis of Cantharidin Derivative DCZ5418 As a TRIP13 Inhibitor with Anti-Multiple Myeloma Activity in Vitro and in Vivo

Discovery of Bis-imidazolecarboxamide Derivatives as Novel, Potent, and Selective TNIK Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis

Synthesis of amide derivatives containing the imidazole moiety and evaluation of their anti‐cardiac fibrosis activity

Discovery and Optimization of Triazine Derivatives As ROCK1 Inhibitors: Molecular Docking, Molecular Dynamics Simulations and Free Energy Calculations

Discovery of 1,8-naphthalidine derivatives as potent anti-hepatic fibrosis agents via repressing PI3K/AKT/Smad and JAK2/STAT3 pathways

Discovery of Chiral 1,4-Diarylazetidin-2-one-Based Hydroxamic Acid Derivatives as Novel Tubulin Polymerization Inhibitors with Histone Deacetylase Inhibitory Activity

Design, Synthesis and Evaluate of Indazolylaminoquinazoline Derivatives As Potent Tropomyosin Receptor Kinase (TRK) Inhibitors

Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors.

New daphnane diterpenoidal 1,3,4-oxdiazole derivatives as potential anti-hepatoma agents: Synthesis, biological evaluation and molecular modeling studies

Discovery of ErbB/HDAC Inhibitors by Combining the Core Pharmacophores of HDAC Inhibitor Vorinostat and Kinase Inhibitors Vandetanib, BMS-690514, Neratinib, and TAK-285

Discovery of highly potent tubulin polymerization inhibitors: Design, synthesis, and structure-activity relationships of novel 2,7-diaryl-[1,2,4]triazolo[1,5-a]pyrimidines